Reviewed by: Jose Baldazo, BSN, RN
If you've lost significant weight on a GLP-1 medication like semaglutide or tirzepatide, you may have noticed something the scale doesn't show: skin that feels looser than expected, especially around the face, upper arms, and abdomen. Dermatologists have started calling this "GLP-1 skin" — and it's become common enough that it now has its own body of research behind it.
This isn't a flaw in your results, and it isn't something GLP-1 medications cause directly. Here's what's actually happening, what current research says helps, and what to know before you start a program if this is a concern for you.
What's actually causing it
Skin laxity after GLP-1-related weight loss comes down to a few overlapping mechanisms, not a single cause:
Collagen and elastin decline. GLP-1RA effects on subcutaneous adipose tissue and the dermal extracellular matrix can include dehydration and nutrient deficiencies, potentially reducing skin quality and fibroblast function, decreasing collagen production, and increasing the breakdown of collagen, elastic fibers, and glycosaminoglycans — the combination responsible for elasticity and firmness.
Speed of weight loss matters more than the medication itself. Skin laxity after weight loss isn't new and isn't caused by GLP-1 medications themselves — it's a longstanding response to rapid fat loss outpacing skin's ability to adapt, seen historically after bariatric surgery too.
Volume loss compounds the effect, especially in the face — GLP-1 users may notice less facial fullness, sagging skin, wrinkles, and crepe-like texture, with rapid weight loss identified as a key contributor.
Hormonal status changes the picture. Older patients, particularly postmenopausal women, are more likely to experience skin laxity due to collagen and elastin loss tied to both age and declining estrogen — a factor that can compound GLP-1-related changes rather than cause them independently.
The reassuring part: research indicates that changes in collagen composition and skin elasticity associated with GLP-1RAs are reversible with appropriate intervention and time — this isn't necessarily permanent.
What actually helps — supporting skin from the inside
Learn More: GLP-1 & Medical Weight Loss
The research on why GLP-1 skin happens points to three overlapping drivers: nutrient and hydration deficits, declining collagen synthesis, and — for many patients — hormonal shifts. That's useful, because it means the most direct ways to support skin quality during and after GLP-1-related weight loss aren't cosmetic procedures at all — they're addressing those underlying drivers directly.
IV therapy for hydration and nutrient repletion. The literature on GLP-1 skin specifically points to dehydration and nutrient deficiencies as part of the mechanism behind reduced skin quality and collagen production. IV therapy is a direct way to address that gap, replenishing fluids and micronutrients (vitamin C, zinc, and others involved in collagen synthesis) that can run low during rapid weight loss and reduced appetite. Learn More: IV Therapy
Hormone optimization (HRT), where relevant. Estrogen decline is independently linked to collagen and elastin loss — older patients, particularly postmenopausal women, are more likely to experience skin laxity due to that hormonal shift, separate from any GLP-1 use. For perimenopausal and postmenopausal patients, hormone optimization can address a compounding factor that GLP-1-specific advice alone won't touch. Learn More: HRT
Read: "Why Longevity Medicine Has Ignored Women"
Peptide therapy targeting collagen synthesis. GHK-Cu — a naturally occurring copper peptide — has the most direct human clinical evidence of any peptide studied for skin firmness and collagen support, evaluated in placebo-controlled topical trials. It's also one of the four components in blends like GLOW and KLOW. A peptide protocol built around collagen-supportive research is a more direct line to the mechanism at play than a procedure that works on the skin's surface. Learn More: Peptide Therapy
Targeted nutrition and supplement support. Adequate protein intake supports the same collagen-elastin matrix implicated in laxity, and specific micronutrients (vitamin C, zinc, copper) are required cofactors for collagen synthesis itself. A supplement and nutrition plan built around active weight loss — not a generic multivitamin — is one of the more overlooked levers here. Shop: Weight Loss Supplements
Where procedural treatments fit: dermatology-based options like radiofrequency microneedling or biostimulatory injections do exist and some patients pursue them alongside — not instead of — addressing the underlying nutrient, hydration, and hormonal picture. If a patient is also seeing a dermatologist, these approaches are complementary rather than competing.
The realistic timeline
There's often improvement in skin laxity after weight stabilizes — a period of roughly 6–12 months of skin remodeling at the new weight, according to Columbia University dermatologist Dr. Lindsey Bordone. That means the right first step for many patients isn't an aggressive intervention immediately after reaching a weight goal — it's a skin assessment once weight has stabilized, to see how much natural remodeling has already occurred.
Prevention matters as much as treatment
The research is consistent on one point: the pace of weight loss is a determining factor, since rapid volume loss can exceed skin's ability to adapt progressively. If someone is earlier in a GLP-1 program, a few things reduce the odds of significant laxity later:
Adequate protein intake to support the collagen-elastin matrix during active weight loss
Resistance training to preserve muscle mass, which helps maintain the underlying structure skin relies on
Hydration and nutrient intake, since dehydration and nutrient deficiencies are part of the mechanism connecting rapid weight loss to reduced skin quality
A gradual pace where medically appropriate, discussed with the prescribing provider rather than pushed for the fastest possible result
Learn More: Functional Medicine
The bottom line
Skin laxity after GLP-1-related weight loss is common, well-documented, and — per current research — largely reversible with the right combination of time, targeted nutrition, and support for the underlying hydration, nutrient, and hormonal factors involved. It's not a sign that anything went wrong. The most effective plans treat it as its own phase of care, addressing root causes rather than only the surface.
Book: Free Info Call - Weight Loss
Frequently Asked Questions
Does Ozempic or semaglutide directly cause skin laxity? Not directly. Skin laxity after weight loss isn't new and isn't caused by GLP-1 medications themselves — it results from the pace and amount of fat loss exceeding skin's ability to adapt, a pattern seen with rapid weight loss generally, including after bariatric surgery.
How long does GLP-1 skin last? Many patients see improvement within 6–12 months of weight stabilization as skin naturally remodels. Research also indicates the underlying collagen and elasticity changes are generally reversible with time and appropriate treatment.
What's the best treatment for skin laxity after weight loss? There's no single best option. The most direct approaches address the underlying drivers — hydration and nutrient repletion (IV therapy), collagen-supportive peptide protocols, hormone optimization where estrogen decline is a factor, and targeted nutrition. A qualified provider can help determine which of these matters most for your specific situation.
Can skin laxity be prevented while on a GLP-1? It can be reduced, though not always fully prevented. Adequate protein intake, resistance training, hydration, and a medically appropriate pace of weight loss all support skin quality during active weight loss.
Sources & Further Reading
Medscape — Explaining Skin Laxity After a Patient's Drastic GLP-1 Medication Weight Loss. Clinical commentary from dermatologists at Columbia University and elsewhere on mechanisms and timeline. https://www.medscape.com/viewarticle/explaining-skin-laxity-after-patients-drastic-glp-1-2025a1000w0t
PubMed — The Potential Role of Topical Skincare Approaches After GLP-1 Receptor Agonist Use and Rapid Weight Loss. Literature review on mechanisms and topical treatment evidence. https://pubmed.ncbi.nlm.nih.gov/42210880/
National Library of Medicine (PMC) — GLP-1RA and the Possible Skin Aging. Review of proposed biological mechanisms connecting GLP-1RA use, rapid weight loss, and skin aging. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370548/
ClinicalTrials.gov — Study on the Efficacy and Safety of PLLA Injections for Improving Facial Laxity Following GLP-1 Analog Therapy. Active clinical trial record, 2026. https://clinicaltrials.gov/study/NCT07478198
(Compliance note: this content describes treatment categories generally and should not be read as claiming a specific outcome or timeline for any individual patient. Confirm any specific device or product claims with your compliance contact before publishing, particularly if referencing a specific branded treatment your clinic offers.)